Ngenla 20 mg (Somatrogon SOLUTION) 20 MG

NGENLA 20 MG is a somatropin solution designed for subcutaneous use. This medication is commonly used to treat growth hormone deficiencies in children and adults. It supports growth and development by replenishing the body's natural growth hormone levels.

Strength

20 MG

Manufacturer / TM Owner

PFIZER CANADA ULC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

NGENLA 20 MG is primarily used to address growth hormone deficiencies. It helps children and adults who lack sufficient growth hormone to grow and develop properly. This solution is administered subcutaneously to support various physiological functions related to growth and metabolism.

Side Effects

Common effects of NGENLA 20 MG may include redness or swelling at the injection site. Some individuals might experience joint or muscle pain, headaches, or changes in blood sugar levels. These effects are generally mild and temporary, but persistent issues should be discussed with a healthcare provider.

Precautions & Warnings

NGENLA 20 MG should be handled with care, ensuring proper storage and administration techniques. It is important to follow the prescribed guidelines for subcutaneous injection to minimize the risk of infection or irritation. Always consult a healthcare professional before starting or adjusting any medication regimen.

Avoid Interactions

NGENLA 20 MG may interact with other medications, particularly those that affect growth hormone levels or metabolism. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Alcohol and certain supplements might also influence the effectiveness of this solution.

Frequently Asked Questions

NGENLA 20 MG is used to treat growth hormone deficiencies in children and adults, supporting growth and development.

NGENLA 20 MG is administered subcutaneously, typically through injection.

Common side effects may include redness or swelling at the injection site, joint or muscle pain, headaches, and changes in blood sugar levels.

Yes, NGENLA 20 MG can be used by adults to address growth hormone deficiencies.

Precautions include proper storage, correct administration techniques, and consulting a healthcare provider before starting or adjusting the medication.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.